Detalhe da pesquisa
1.
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Lancet Reg Health Eur
; 42: 100940, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813536
2.
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.
Lancet Reg Health Eur
; 41: 100912, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38665620
3.
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Eur J Cancer
; 189: 112920, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277262
4.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509300
5.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173031
6.
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Explor Target Antitumor Ther
; 2(5): 448-464, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045702
7.
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.
Cancers (Basel)
; 13(10)2021 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34067823
8.
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Eur J Cancer
; 149: 49-60, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823362
9.
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
J Clin Med
; 10(5)2021 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33801320